Murray I A, Cann P A, Day P J, Derrick J P, Sutcliffe M J, Shaw W V, Leslie A G
Department of Biochemistry, University of Leicester, UK.
J Mol Biol. 1995 Dec 15;254(5):993-1005. doi: 10.1006/jmbi.1995.0671.
The antibiotic fusidic acid and certain closely related steroidal compounds are potent competitive inhibitors of the type I variant of chloramphenicol acetyltransferase (CATI). In the absence of crystallographic data for CATI, the structural determinants of steroid binding were identified by (1) construction in vitro of genes encoding chimaeric enzymes containing segments of CATI and the related type III variant (CATIII) and (2) site-directed mutagenesis of the gene encoding CATIII, followed by kinetic characterisation of the substituted variants. Replacement of four residues of CATIII (Gln92, Asn146, Tyr168 and Ile172) by their equivalents from CATI yields an enzyme variant that is susceptible to competitive inhibition by fusidate with respect to chloramphenicol (Ki = 5.4 microM). The structure of the complex of fusidate and the Q92C/N146F/Y168F/I172V variant, determined at 2.2 A resolution by X-ray crystallography, reveals the inhibitor bound deep within the chloramphenicol binding site and in close proximity to the side-chain of His195, an essential catalytic residue. The aromatic side-chain of Phe146 provides a critical hydrophobic surface which interacts with non-polar substituents of the steroid. The remaining three substitutions act in concert both to maintain the appropriate orientation of Phe 146 and via additional interactions with the bound inhibitor. The substitution of Gln92 by Cys eliminates a critical hydrogen bond interaction which constrains a surface loop (residues 137 to 142) of wild-type CATIII which must move in order for fusidate to bind to the enzyme. Only two hydrogen bonds are observed in the CAT-fusidate complex, involving the 3-alpha-hydroxyl of the A-ring and both hydroxyl of Tyr25 and NE2 of His195, both of which are also involved in hydrogen bonds with substrate in the CATIII-chloramphenicol complex. In the acetyl transfer reaction catalysed by CAT, NE2, of His195 serves as a general base in the abstraction of a proton from the 3-hydroxyl of chloramphenicol as the first chemical step in catalysis. The structure of the CAT-inhibitor complex suggests that deprotonation of the 3-alpha-hydroxyl of bound fusidate by this mechanism could produce an oxyanion nucleophile analogous to that seen with chloramphenicol, but one which is incorrectly positioned to attack the thioester carbonyl of acetyl-CoA, accounting for the observed failure of CAT to acetylate fusidate.
抗生素夫西地酸和某些密切相关的甾体化合物是氯霉素乙酰转移酶I型变体(CATI)的强效竞争性抑制剂。由于缺乏CATI的晶体学数据,通过以下方法确定了甾体结合的结构决定因素:(1)在体外构建编码含有CATI和相关III型变体(CATIII)片段的嵌合酶的基因;(2)对编码CATIII的基因进行定点诱变,随后对取代变体进行动力学表征。用CATI的等效残基取代CATIII的四个残基(Gln92、Asn146、Tyr168和Ile172),得到一种酶变体,该变体在氯霉素方面易受夫西地酸的竞争性抑制(Ki = 5.4 microM)。通过X射线晶体学在2.2 Å分辨率下测定的夫西地酸与Q92C/N146F/Y168F/I172V变体的复合物结构显示,抑制剂结合在氯霉素结合位点深处,并且紧邻His195的侧链,His195是一个必需的催化残基。Phe146的芳香侧链提供了一个关键的疏水表面,与甾体的非极性取代基相互作用。其余三个取代协同作用,既保持Phe 146的适当取向,又通过与结合的抑制剂的额外相互作用。用Cys取代Gln92消除了一个关键的氢键相互作用,该相互作用限制了野生型CATIII的一个表面环(残基137至142),夫西地酸要与酶结合,这个环必须移动。在CAT-夫西地酸复合物中只观察到两个氢键,涉及A环的3-α-羟基以及Tyr25的两个羟基和His195的NE2,这两个氢键在CATIII-氯霉素复合物中也参与与底物的氢键形成。在CAT催化的乙酰转移反应中,His195的NE2作为一个通用碱,从氯霉素的3-羟基提取一个质子,这是催化中的第一步化学步骤。CAT-抑制剂复合物的结构表明,通过这种机制使结合的夫西地酸的3-α-羟基去质子化可能产生一个类似于氯霉素的氧阴离子亲核试剂,但它所处的位置不正确,无法攻击乙酰辅酶A的硫酯羰基,这就解释了观察到的CAT不能使夫西地酸乙酰化的现象。